DUBAI, UAE, May 8, 2026 /PRNewswire/ — Robo.ai Inc. (NASDAQ: AIIO) (the “Company” or “Robo.ai”) today announced an agreement to acquire 100% of the equity interest in Neurovia AI Limited (“Neurovia”), a technology company specializing in data processing and compression, for a total consideration of $100 million. The closing of the transaction remains subject to the satisfaction of customary closing conditions.

This acquisition accelerates Robo.ai’s development of foundational infrastructure for physical artificial intelligence. The transaction is structured entirely in stock, reflecting an alignment of core interests and a shared objective to build a global AI infrastructure and machine economy ecosystem.

As the industry transitions from digital AI to physical AI, a primary operational requirement is the efficient storage, processing, transmission, analysis, and management of real-world data. Neurovia’s management noted that video data acts as the primary data inlet in the physical AI era, presenting a continuous challenge regarding the global compression, real-time transmission, edge processing, and cloud analysis of the massive data generated by AI machines. Management stated that Neurovia’s underlying technology directly addresses this industry requirement and that integrating with Robo.ai will contribute to building a data infrastructure for smart devices worldwide.

Following the acquisition, Robo.ai plans to upgrade its relevant business lines from traditional video codec operations to a comprehensive global AI video data infrastructure platform. This upgraded infrastructure will support various intelligent terminals and core use cases, encompassing robotaxis, autonomous vehicles, unmanned delivery systems, smart cities, AI camera networks, drone platforms, humanoid robots, and smart manufacturing systems.

The transaction structure is designed to ensure a long-term alignment of strategic and commercial interests. The acquisition consideration will be paid entirely through the issuance of Robo.ai’s Class B ordinary shares. This all-stock structure allows Robo.ai to maintain a solid balance sheet and adequate liquidity to fund ongoing research and development as well as market expansion, while demonstrating the Neurovia team’s recognition of the Company’s development potential. To ensure operational continuity and steady business growth, the parties have established a strict equity lock-up mechanism. All issued shares will be subject to a complete lock-up for the first three years following the closing. Starting in the fourth year, the shares will vest gradually over a subsequent five-year period, resulting in a total lock-up schedule of eight years. This structure is intended to secure the long-term core interests of all shareholders and ensure the Neurovia team’s commitment to the Robo.ai ecosystem.

Over the next decade, Robo.ai plans to focus on the closed-loop integration of AI hardware, video data, edge AI, and blockchain to build a complete machine economy ecosystem. The Company is actively advancing its strategic footprint in core markets across the Middle East and Asia, focusing on global commercial opportunities in smart cities, sovereign AI infrastructure, and autonomous driving. Recognizing real-world data as a core asset in the AI economy, Robo.ai will continue to explore application scenarios, including on-chain identities for AI devices, video data assetization, AI data rights confirmation, and stablecoin payments, aiming to construct a highly coordinated global AI machine network.

About Neurovia AI Limited

Neurovia AI Limited (www.neuroviaai.ae) is a provider of AI data processing and compression technology. The company focuses on AI video compression, edge computing, and real-time analysis to resolve data transmission and computation bottlenecks. By building low-latency data infrastructure for the physical AI era, Neurovia supports applications across autonomous driving, smart cities, unmanned devices, and smart manufacturing.

About Robo.ai Inc.

Robo.ai Inc. (NASDAQ: AIIO) is a technology company dedicated to building a leading global artificial intelligence machine economy platform. Its mission is to integrate “AI Software, Intelligent Hardware, and Smart Assets” to construct a unified AI operating system and an ecosystem empowered by blockchain, pioneering an intelligent future.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those anticipated; for further details, please refer to the Company’s filings with the U.S. Securities and Exchange Commission.

View original content to download multimedia:https://www.prnewswire.com/news-releases/roboai-announces-acquisition-of-data-processing-and-compression-technology-company-neurovia-building-data-infrastructure-for-the-machine-economy-302766695.html

SOURCE Robo.ai Inc.

GOTHENBURG, Sweden, May 8, 2026 /PRNewswire/ — The recruitment represents a significant strategic addition to the company as it continues the development of its innovative drug platform within pain and inflammatory diseases. Dr. Lundberg has had a long and highly successful international career spanning both academia and the global pharmaceutical industry. He began his career as a researcher and professor at the Karolinska Institute and established himself at a very early stage as one of the world’s 100 most cited scientists.

He subsequently joined AstraZeneca, where he held leading positions within research and development before being recruited to Eli Lilly in the United States. There, he served for many years as Global Head of Research and was ultimately responsible for building the research portfolio that contributed to Eli Lilly becoming what is today the world’s highest valued pharmaceutical company.

Under Dr. Lundberg’s leadership, several GLP 1 based medicines were developed, including therapies within the same drug class as Ozempic. These treatments from Eli Lilly have today become dominant in the treatment of metabolic diseases such as obesity and represent one of the pharmaceutical industry’s most successful therapeutic areas. In addition to medicines for obesity and diabetes, he also successfully developed treatments for Alzheimer’s disease and pain. Among other achievements, he was a pioneer in the development of antibody therapies for migraine and the extremely severe disorder cluster headache.

Oblique Therapeutics is developing, among other programs, next generation antibody based ion channel therapeutics with a focus on TRPV1 and pain. Dr. Lundberg’s scientific expertise and extensive experience in translational research, drug development, strategic portfolio building, as well as his broad industrial and academic network, will play an invaluable role in the continued development of Oblique’s operations.

Fun fact: Dr. Lundberg originates from Munkfors in the province of Värmland, Sweden, a region that has produced a disproportionately large number of successful Swedes, including Tage Erlander, Erik Gustaf Geijer, Lars Lerin, Bosse Parnevik and many others. Before dedicating himself fully to medicine and research, he was also a successful ice hockey player, including playing in both the United States and Canada.

“I have been active in the research field surrounding capsaicin, TRPV1 and pain since its very earliest days, and it is extremely exciting to see the progress now being made by Oblique Therapeutics. The company’s antibody based strategy has the potential to create a new and clear differentiation compared with small molecule TRPV1 blockers, which have been important in validating the significance of this ion channel in pain, but which have been limited by side effects during systemic treatment. The opportunity to contribute to the development of what could become a transformative treatment for patients suffering from chronic pain is therefore both scientifically and personally highly inspiring,” says Dr. Lundberg.

“We are extremely pleased and proud that Dr. Jan Lundberg has chosen to engage with Oblique Therapeutics. His unique scientific stature, industrial experience and proven ability to build successful pharmaceutical portfolios are invaluable to the company as we continue our development,” says Christer Nordstedt, CEO of Oblique Therapeutics.

For further information, please contact

Christer Nordstedt MD PhD
CEO
Oblique Therapeutics AB
Box 40091-9037
Datavägen 15D
436 32 Askim
Mobil: +46 70 251 40 33
Email: christer.nordstedt@obliquet.com
Web: www.obliquet.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oblique-therapeutics-ab/r/oblique-therapeutics-today-announced-that-dr–jan-lundberg-has-joined-the-company-as-scientific-advi,c4346414

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/oblique-therapeutics-today-announced-that-dr-jan-lundberg-has-joined-the-company-as-scientific-advisor-302766804.html

Gracie debuts as the first cross-domain agentic capability in GRC, convening AI experts across risk, compliance, audit and third-party domains on a single task

LONDON , May 8, 2026 /PRNewswire/ — SureCloud Ltd. has two decades of experience as a leading provider of Governance, Risk, and Compliance (GRC) solutions trusted by organisations from global banks to some of the UK’s largest retailers. Its latest release introduces persona-based AI agents that fill specialist positions across a GRC programme, execute against organisation’s own expertise and operate within a governed architecture purpose-built for regulated functions.

The capacity problem behind compliance fatigue

GRC has been a discipline of skilled people doing manual work. That equation has now become mathematically impossible. SureCloud research finds that 49 per cent of UK enterprises struggle to keep up with five or more major regulations at once, and 57 per cent say budget constraints the hiring needed to close them.

Security risk and compliance professionals are not short of expertise. They are short of the capacity to execute every assessment, review every control, chase every document and produce every report at the pace now required.

A virtual GRC team, not another co-pilot

This is a major enhancement to SureCloud’s GRC platform, moving beyond common conversational capabilities to true autonomous agents capable of executing over 200 distinct actions within the platform. Agents give teams reach, not taking jobs but allowing people to work more effectively across repetitive workloads.

SureCloud ships Personas for every role, from Risk SMEs to Privacy SMEs. Customers can invoke this virtual team for reasoning on specific tasks and then define how each agent operates within their policies and governance structures.

Skills then codify how the specific GRC activity is performed, taking the best expertise from SureCloud or their own business, and ensuring repeatable consistency.

Nick Rafferty, CEO, SureCloud, said:

“For two decades, GRC has been a discipline of skilled people doing manual work. The expertise was always there. The execution capacity never was. Gracie changes that equation by giving every person an agent counterpart that carries their workload, operates to their standard and frees them to do the work only a senior expert can do. This is the moment GRC stops being a record-keeping exercise and starts being an executable one.”

SureCloud was recognised this month in three categories of the Gartner Hype Cycle for Cyber-Risk Management, 2026 and Gartner’s new Innovation Insight: Cyber GRC.

Logo – https://mma.prnewswire.com/media/2975638/SureCloud_Logo.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/surecloud-launches-gracie-ai-a-virtual-grc-team-to-fix-the-broken-operating-model-302766805.html